Evotec shares surge 11.11% premarket after Berenberg upgrades to Buy with €10 price target.

Evotec surged 11.11% in premarket trading following a series of positive analyst actions. Berenberg upgraded the stock to "Buy" from "Neutral," raising its price target to €10, citing Evotec's position at the intersection of rising pharmaceutical outsourcing demand and cost-efficient R&D innovation. Additionally, the firm initiated coverage with a "Buy" rating, emphasizing the company's global recognition as a contract research leader and the valuation potential of its platforms. These analyst upgrades directly aligned with the sharp premarket rally, as the firm highlighted Evotec's ability to capitalize on industry trends and deliver value through its drug discovery solutions. While the company's upcoming presentation at the SLAS2026 conference and future financial milestones were mentioned in broader market commentary, the immediate catalyst was the upgraded analyst ratings, which underscored confidence in Evotec's strategic positioning and growth prospects.